SGLT-2 Inhibitors and Cardio-renal Outcomes: Translating the Data into Practice
Published: 12 November 2021
6m 30sPart 2 Screening for CKD
8m 25sPart 3 Treatment Options in CKD
Following the release at ESC 2021 of updated guidelines for the diagnosis and treatment of acute and chronic heart failure, Dr Shelley Zieroth (University of Manitoba, CA), Prof Hiddo L Heerspink (University Medical Center, Groningen, NL) and Prof Kamlesh Khunti (University of Leicester, UK) discuss the implications for practice.
This three-part series, 'SGLT-2 Inhibitors and Cardio-renal Outcomes: Translating the Data into Practice', brings together three experts to review the implications for pathophysiology, screening and treatment strategies.
Download infographic ‘SGLT-2 inhibitors and cardio-renal outcomes’
- Recall the existing relationship between chronic kidney disease and cardiovascular disease for patients with and without type 2 diabetes.
- Consider the global burden of CKD, including for patients with type 2 diabetes, and be aware of existing guidelines for screening.
- Review treatment options for the treatment of patients with chronic kidney disease, and the role of SGLT2i therapies in available strategies.
- Renal specialists
More from this programme
|Cardio-renal Pathophysiology||Watch now|
Screening for CKD
|Screening for CKD||Watch now|
Treatment Options in CKD
|Treatment Options in CKD||Watch now|
Director of the Heart Failure and Heart Transplant Clinics
Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St. Boniface Hospital in Winnipeg, CA.
She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba. She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Immediate Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She serves as Co-Chair of Canada’s largest annual heart failure meeting, HF Update and serves as Scientific Planning Committee Chair for the Canadian Cardiovascular Congress hosted by the Canadian Cardiovascular Society. She is currently President-elect of the Federation of Medical Women of Canada.
Professor of Primary Care Diabetes and Vascular Medicine
Professor Kamlesh Khunti is the Professor of Primary Care Diabetes and Vascular Medicine at the University of Leicester, UK. He is Co-Director of the Leicester Diabetes Centre and leads a research group that is currently working on the early identification of, and interventions with, people who have cardiometabolic disease or are at increased risk of developing cardiometabolic diseases.
His work has influenced national and international guidelines on the screening and management of people with diabetes. Professor Khunti is also Director of the UK National Institute for Health Research (NIHR) in Applied Research Collaborations (ARC) East Midlands and Director of The Real World Evidence Unit and Centre for BME Health. He is a NIHR Senior Investigator and Principal Investigator on several major national and international studies. He is the National NIHR ARC Theme Lead for Multimorbidity and Ethnicity and Diversity. He is also Honorary Visiting…
Prof Hiddo Heerspink’s is a Clinical Pharmacologist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen, the Netherlands. he also serves as a Visiting Professor at the University of New South Wales in Sydney, Australia. Prof Heerspink's research interests include treatment strategies and therapeutic approaches for the treatment of renal and cardiovascular disease in patients with diabetes.